Business, News OcuTerra Announces Topline Data from Phase 2 DR:EAM Trial Evaluating Nesvategrast (OTT166 5%) for Patients with Diabetic Retinopathy by Business Wire • 2024/03/14 • 0 Comments BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics announces topline data from the Phase 2 DR:EAM clinical trial. Full Story →